Cohort stratification

We use our PIMS platform to select patients whose samples show they are likely to respond well to specific targeted medicines, supporting the development of precision treatments tailored to those patients. To achieve this, we leverage our access to patients and their pathological tissues. Our prospective indication-agnostic tissue collection and biobanking capabilities allow us to work directly on patient material.

PIMS is a label-free platform which analyses patients’ cells or tissues to identify their biological responses to drug candidates, or already approved drugs, enabling:

• Precise patient stratification: Beyond demographics, the platform identifies patients most likely to benefit from a drug, increasing trial success.
• Biomarker discovery: The platform uncovers new biomarkers, which can predict treatment responses and aid in earlier diagnoses. These biomarkers also drive the development of therapies targeting specific disease pathways for more effective treatments.